适形放疗联合替吉奥与吉西他滨治疗局部晚期胰腺癌的疗效观察被引量：10

Observation on the clinical efficiency of conformal radiotherapy combined with S-1 plus gemcitabine in patients with locally advanced pancreatic cancer

原文传递

导出

摘要目的:探讨适形放疗联合替吉奥与吉西他滨治疗局部晚期胰腺癌的疗效和安全性。方法:64例局部晚期胰腺癌患者,采用替吉奥胶囊(S-1)与吉西他滨化疗方案:替吉奥40～50 mg/次,bid,第1～14天;吉西他滨800～1 000 mg·m-2,第1、8天,4周为1周期;连用1～2个周期。同步三维适形放疗从第1天开始,总剂量(DT)50.4 Gy,每天1次,每次1.8 Gy,每周5d,连续5.5周。治疗结束4周后复查CT测量病灶体积改变,检测肿瘤标志物水平,用实体瘤疗效反应的评价标准评价治疗效果,根据WHO标准评价不良反应。结果:64例晚期胰腺癌患者,均完成放化疗,无完全缓解(CR),部分缓解(PR)43.8%(28/64),稳定(SD)45.3%(29/64),进展(PD)10.9%(7/64);治疗有效率(CR+PR)为43.8%(28/64)。中位生存期10个月(8.4～11.6个月),疾病无进展生存期6.0个月(4.6～7.4个月),1年生存率为40.6%。主要不良反应表现为白细胞减少、贫血、血小板减少、恶心、呕吐和疲乏等,患者均能够耐受。结论:适形放疗联合替吉奥与吉西他滨治疗局部晚期胰腺癌近期疗效较好,不良反应可以耐受,值得临床进一步研究。 OKJECTIVE To investigate the effects and side effects of regimen S-1 plus gemcitabine combined concurrent con-formal radiotherapy for patients with locally advanced pancreatic cancer. METHODS Sixty-four patients with locally advancedpancreatic cancer were enrolled. S-1 was administered at a dose of 80- 100 mg·d^-1 from day 1 to 14 and gemcitabine was ad-ministered at a dose of 800- 1 000 mg·m^-2 on d1, d8, repeated every 4 weeks. The concurrent three-dimensional conformal ra-diation therapy was delivered in 1.8 Gy daily fractions to a total dose of 50. 4 Gy over 5.5 weeks. Efficacy and toxicities wereevalualed according to RECIST criteria and WHO＇s criterion. RESULTS All the patients were eligible. Of 64 patients, 28 casesachieved PR, 29 cases achieved SD and 7 cases achieved PD. The overall response rate （CR ＋ PR） was 43.8% （28/64）. Themedian PFS was 6. 0 months （95% CI： 4. 6- 7.4 months） with a median overall survival of 10. 0 months （95% CI： 8. 4 - 11. 6months） and l-year survival rate of 40. 6%. The major adverse events included leucopenia, thrombocytopenia, anaemia, nause-a, vomiting and fatigue. CONCLUSION Regimen S-1 plus gemcitabine combined with conformal radiotherapy shows favorableefficacy for locally advanced pancreatic cancer and side effects were tolerable. The long-term results still need to be further ob- served.

作者刘学芬李刚冉文华张力朱川任必勇彭东刘华文莫小飞

机构地区重庆三峡中心医院肿瘤防治研究所

出处《中国医院药学杂志》 CAS CSCD 北大核心 2013年第6期475-478,共4页 Chinese Journal of Hospital Pharmacy

基金重庆市医学重点研究室建设项目资助(编号:2007-14)

关键词胰腺癌适形放疗替吉奥吉西他滨 pancreatic cancer conformal radiotherapy S-1 gemcitabine

分类号 R969 [医药卫生—药理学]

引文网络
相关文献

参考文献12

1Freelove R, Walling AD. Pancreatic cancer: diagnosis and man agement [J]. Am Faro Physician,2006,73(3):485-402.
2楼文晖.胰腺癌的非手术治疗进展[J].中国实用外科杂志,2008,28(2):90-92. 被引量：4
3张俊,陆嘉德,彭承宏,李宏为.胰腺癌辅助治疗的争议与共识[J].中国癌症杂志,2009,19(8):580-584. 被引量：8
4Regine WF, Winter KA, Abrams R, et al Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemo- therapy after resection of pancreatic adenocarcinoma: 5 year a nalysis of the U. S. lntergroup/RTOG 9704 phase Ⅲ Irial[J]. Ann Surg Oncol, 2011,18(5) :1319-1326.
5Gastrointestinal Tumor Study Group. Treatment of locally un resectable carcinoma of the pancreas: comparison of com- bined--modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone[J]. J Natl Cancer Inst, 1988,80( 5 ) : 751-755.
6孙燕周际昌.临床肿瘤内科手册[M].北京：人民卫生出版社,1996.138.
7Cox JD, Stetz J, Pajak TF. Toxicily criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organi zation for Research and Treatment of Cancer (EORTC) [J]. Int J Radiat Oncol Biol Phys, 1995, 31 (5) : 1341-1346.
8Ueno H, Okusaka T, Ikeda M, etal. An early phase 11 study of S-1 in patients with metastatic pancreatic cancer[J]. Oncol- ogy, 2005,68(3) : 171-178.
9Okusaka T, Funakoshi A, Furuse J,et al. A late phase Ⅱ study of 8-1 for metastatic pancreatic cancer[J]. Cancer Che- mother Pharmacol, 2008,61 (5):615-621.
10Stomiolo AM, Enas NH, Brown CA, et al. An investigation news drug treatment program for patients with gemeitahine: results for over 3000 patients with pancreatic carcinoma[J]. Cancer, 1999,85(6) : 1261-1268.

二级参考文献28

1Moore M J, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [ J ] . J Clin Oncol, 2007, 25(15): 1960-1966.
2Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase Ⅲ trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer [J] .J Clin Oncol, 2009,27(13):2231-2237.
3Loos M, Kleeff J, Friess H, et al. Surgical treatment of pancreatic cancer [ J ] . Ann N Y Acad Sci, 2008, 1138: 169- 180.
4Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal [ J ] . Drugs, 2007, 67(16): 2293-2310.
5Muhammad WS. Controversies in the adjuvant treatment of pancreatic adenocarcinoma [ J ] . J Pancreas, 2007, 8(5):545- 552.
6Moertel CG, Frytak S, Hahn RG, el al. Therapy of locally unreseetable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads_5-fluorouracil), and high dose radiation + 5-fluorouraeil: The Gastrointestinal Tumor Study Group[ J ] . Cancer, 1981, 48(8): 1705-1710.
7Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer [ J ] . Cancer, 1987, 59(12): 2006-2010.
8Yeo C J, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience [ J ] . Ann Surg, 1997, 225(5): 621-636.
9Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer [ J ] . Int J Radiat Oncol Biol Phys, 2000, 48(5): 1483-1487.
10Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouraeil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer cooperative group [ J ] .Ann Surg, 1999, 230(6): 776-782.